MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a ...

Citing people familiar with the matter, the report suggested two companies have been negotiating with Cidara over a sale, and ...

Strategic transaction supports the advancement of Decoy’s rapid computational design and manufacturing of innovative peptide ...

Q3 2025 Earnings Call Transcript November 13, 2025 Operator: Greetings. Welcome to the PDS Biotechnology Corporation’s Third Quarter 2025 Earnings Conference Call. At this time, all participants are ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary ...

Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid ...

Acquisition expands Day One’s portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le)Emi-Le has ...

Strategic transaction supports the advancement of Decoy's rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP3ACT platform Combined company has ...

MONTREAL, Nov. 13, 2025 /CNW/ - Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep (R) (belantamab mafodotin) -- a critical new ...

Good morning, ladies and gentlemen, and welcome to the Cellectar Biosciences' Third Quarter 2025 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025. I ...

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) ...